$APVO SEC Filings

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

This Amendment No. 6 (this “Amendment”), dated as of October 23, 2026, to the Rights Agreement, dated November 8, 2020 (as amended and/or restated from time to time, the “Rights Agreement”), is entered into by and between Aptevo Therapeu...

Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment

Company making critical progress in scalable manufacturing and preparing the lead trispecific candidate for future human testing

On September 22, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is desc...